Rušanac Anamarija, Škibola Zara, Matijašić Mario, Čipčić Paljetak Hana, Perić Mihaela
Department of Intercellular Communication, Center for Translational and Clinical Research, School of Medicine, University of Zagreb, Šalata 2, 10000 Zagreb, Croatia.
BIMIS-Biomedical Research Center Šalata, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Int J Mol Sci. 2025 Jul 14;26(14):6745. doi: 10.3390/ijms26146745.
Maintaining a balanced skin microbiota is essential for skin health, whereas disruptions in skin microbiota composition, known as dysbiosis, can contribute to the onset and progression of various skin disorders. Microbiota dysbiosis has been associated with several inflammatory skin conditions, including atopic dermatitis, seborrheic dermatitis, acne, psoriasis, and rosacea. Recent advances in high-throughput sequencing and metagenomic analyses have provided a deeper understanding of the skin microbial communities in both health and disease. These discoveries are now being translated into novel therapeutic approaches aimed at restoring microbial balance and promoting skin health through microbiome-based interventions. Unlike conventional therapies that often disrupt the microbiota and lead to side effects or resistance, microbiome-based products offer a more targeted strategy for preventing and managing inflammatory skin diseases. These products, which include probiotics, prebiotics, postbiotics, and live biotherapeutic agents, are designed to modulate the skin ecosystem by enhancing beneficial microbial populations, suppressing pathogenic strains, and enhancing immune tolerance. As a result, they represent a promising class of products with the potential to prevent, manage, and even reverse inflammatory skin conditions. However, realizing the full therapeutic potential of microbiome-based strategies in dermatology will require continued research, robust clinical validation, and clear regulatory frameworks.
维持皮肤微生物群的平衡对皮肤健康至关重要，而皮肤微生物群组成的破坏，即生态失调，可能会导致各种皮肤疾病的发生和发展。微生物群生态失调与多种炎症性皮肤病有关，包括特应性皮炎、脂溢性皮炎、痤疮、银屑病和酒渣鼻。高通量测序和宏基因组分析的最新进展使人们对健康和疾病状态下的皮肤微生物群落有了更深入的了解。这些发现目前正被转化为新的治疗方法，旨在通过基于微生物组的干预措施来恢复微生物平衡并促进皮肤健康。与传统疗法常常破坏微生物群并导致副作用或耐药性不同，基于微生物组的产品为预防和管理炎症性皮肤病提供了一种更具针对性的策略。这些产品包括益生菌、益生元、后生元以及活体生物治疗剂，旨在通过增加有益微生物数量、抑制致病菌株和增强免疫耐受性来调节皮肤生态系统。因此，它们是一类有前景的产品，有可能预防、管理甚至逆转炎症性皮肤病。然而，要充分实现基于微生物组的策略在皮肤病学中的治疗潜力，还需要持续的研究、有力的临床验证以及明确的监管框架。
